Georgiadou S, Gatselis NK, Stefos A, Zachou K, Makaritsis K, Rigopoulou EI, Dalekos GN. Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions. World J Clin Cases 2019; 7(21): 3394-3406 [PMID: 31750324 DOI: 10.12998/wjcc.v7.i21.3394]
Corresponding Author of This Article
George N Dalekos, MD, PhD, Chairman, Full Professor, Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. dalekos@med.uth.gr
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2019; 7(21): 3394-3406 Published online Nov 6, 2019. doi: 10.12998/wjcc.v7.i21.3394
Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions
Sarah Georgiadou, Nikolaos K Gatselis, Aggelos Stefos, Kalliopi Zachou, Konstantinos Makaritsis, Eirini I Rigopoulou, George N Dalekos
Sarah Georgiadou, Nikolaos K Gatselis, Aggelos Stefos, Kalliopi Zachou, Konstantinos Makaritsis, Eirini I Rigopoulou, George N Dalekos, Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa, Larissa 41110, Greece
Nikolaos K Gatselis, Kalliopi Zachou, Konstantinos Makaritsis, Eirini I Rigopoulou, George N Dalekos, Institute of Internal Medicine and Hepatology, University Hospital of Larissa, Larissa 41447, Greece
Author contributions: Makaritsis K, Rigopoulou EI, Dalekos GN made the conception and designed of the work, treated the patients, analyzed and interpreted of the data, critical revision of the manuscript and final approved of the version to be published; Georgiadou S, Gatselis NK, Stefos A, Zachou K treated the patients, made the collection, statistical analysis and interpretation of the data, wrote the first draft of the manuscript and final approved of the version to be published.
Institutional review board statement: The ethical committee of the University Hospital of Larissa approved the protocol which conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.
Informed consent statement: Patients were not required to give informed consent to the study because the retrospective analysis used anonymous clinical data that were obtained after each patient agreed to the treatment schedule by written consent.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No additional data are available.
Corresponding author: George N Dalekos, MD, PhD, Chairman, Full Professor, Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. dalekos@med.uth.gr
Telephone: +30-241-3502285 Fax: +30-241-3501557
Received: June 5, 2019 Peer-review started: June 6, 2019 First decision: September 9, 2019 Revised: September 20, 2019 Accepted: October 15, 2019 Article in press: October 15, 2019 Published online: November 6, 2019 Processing time: 156 Days and 18.5 Hours
Core Tip
Core tip: This retrospective study analysed all adult patients (n = 80) with secondary haemophagocytic lymphohistiocytosis (sHLH) diagnosed in our tertiary care hospital during 2010-2018 paying considerable attention on the treatment schedule and the outcome of patients. In our large cohort, infections were the major cause of sHLH (74% of patients) and therefore, they should be thoroughly investigated in such patients. sHLH still carries a remarkable morbidity and mortality as 15% of patients died within the first month. Early recognition and treatment with intravenous γ-immunoglobulin in association with intravenous corticosteroids seem an efficient treatment option for successful outcome in this life-threatening condition (resolution in 76%; 6-mo survival: 82.5%).
